journal
MENU ▼
Read by QxMD icon Read
search

Blood Cancer Journal

journal
https://www.readbyqxmd.com/read/29099480/prolonged-lymphocytopenia-after-bendamustine-therapy-in-patients-with-relapsed-or-refractory-indolent-b-cell-and-mantle-cell-lymphoma
#1
H Saito, D Maruyama, A M Maeshima, S Makita, H Kitahara, K Miyamoto, S Fukuhara, W Munakata, T Suzuki, Y Kobayashi, H Taniguchi, K Tobinai
This corrects the article DOI: 10.1038/bcj.2015.86.
November 3, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/29099479/the-availability-of-jobs-in-the-biopharmaceutical-industry-is-45-fold-greater-for-hematology-oncology-than-medical-specialties
#2
V Kaestner, V Prasad
This corrects the article DOI: 10.1038/bcj.2017.91.
November 3, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/29053158/prevalence-of-myeloma-precursor-state-monoclonal-gammopathy-of-undetermined-significance-in-12372-individuals-10-49-years-old-a-population-based-study-from-the-national-health-and-nutrition-examination-survey
#3
O Landgren, B I Graubard, S Kumar, R A Kyle, J A Katzmann, K Murata, R Costello, A Dispenzieri, N Caporaso, S Mailankody, N Korde, M Hultcrantz, T M Therneau, D R Larson, J R Cerhan, S V Rajkumar
We studied the prevalence of monoclonal gammopathy of undetermined significance (MGUS) in younger individuals, age 10-49 years, using samples from the National Health and Nutritional Examination Survey (NHANES) III. NHANES prevalence rates were standardized to the 2000 US total population. Among 12 372 individuals (4073 blacks, 4146 Mexican-Americans, 3595 whites, and 558 others), MGUS was identified in 63 persons (0.34%, 95% CI 0.23-0.50). The prevalence of MGUS was significantly higher in blacks (0.88%, 95% CI 0...
October 20, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/29053157/current-applications-of-multiparameter-flow-cytometry-in-plasma-cell-disorders
#4
REVIEW
T Jelinek, R Bezdekova, M Zatopkova, L Burgos, M Simicek, T Sevcikova, B Paiva, R Hajek
Multiparameter flow cytometry (MFC) has become standard in the management of patients with plasma cell (PC) dyscrasias, and could be considered mandatory in specific areas of routine clinical practice. It plays a significant role during the differential diagnostic work-up because of its fast and conclusive readout of PC clonality, and simultaneously provides prognostic information in most monoclonal gammopathies. Recent advances in the treatment and outcomes of multiple myeloma led to the implementation of new response criteria, including minimal residual disease (MRD) status as one of the most relevant clinical endpoints with the potential to act as surrogate for survival...
October 20, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28984867/sodium-fluoride-pet-imaging-as-a-quantitative-pharmacodynamic-biomarker-for-bone-homeostasis-during-anti-dkk1-therapy-for-multiple-myeloma
#5
Y Wang, A J Yee, C Sirard, S Landau, N Raje, U Mahmood
No abstract text is available yet for this article.
October 6, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28984866/bone-marrow-stroma-cells-derived-from-mononuclear-cells-at-diagnosis-as-a-source-of-germline-control-dna-for-determination-of-somatic-mutations-in-acute-myeloid-leukemia
#6
H Mujahed, M Jansson, S Bengtzén, S Lehamnn
No abstract text is available yet for this article.
October 6, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28960192/high-pretreatment-level-of-soluble-interleukin-2-receptor-is-a-robust-prognostic-factor-in-patients-with-follicular-lymphoma-treated-with-r-chop-like-therapy
#7
Y Kusano, M Yokoyama, Y Terui, N Inoue, A Takahashi, H Yamauchi, N Tsuyama, N Nishimura, Y Mishima, K Takeuchi, K Hatake
No abstract text is available yet for this article.
September 29, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28960191/meis2-as-a-critical-player-in-mn1-induced-leukemia
#8
C K Lai, G L Norddahl, T Maetzig, P Rosten, T Lohr, L Sanchez Milde, N von Krosigk, T R Docking, M Heuser, A Karsan, R K Humphries
Meningioma 1 (MN1) is an independent prognostic marker for normal karyotype acute myeloid leukemia (AML), with high expression linked to all-trans retinoic acid resistance and poor survival. MN1 is also a potent and sufficient oncogene in murine leukemia models, strongly dependent on the MEIS1/AbdB-like HOX protein complex to transform common myeloid progenitors, block myeloid differentiation, and promote leukemic stem cell self-renewal. To identify key genes and pathways underlying leukemic activity, we functionally assessed MN1 cell phenotypic heterogeneity, revealing leukemic and non-leukemic subsets...
September 29, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28937974/high-somatic-mutation-and-neoantigen-burden-are-correlated-with-decreased-progression-free-survival-in-multiple-myeloma
#9
A Miller, Y Asmann, L Cattaneo, E Braggio, J Keats, D Auclair, S Lonial, S J Russell, A K Stewart
Tumor-specific mutations can result in immunogenic neoantigens, both of which have been correlated with responsiveness to immune checkpoint inhibitors in highly mutagenic cancers. However, early results of single-agent checkpoint inhibitors in multiple myeloma (MM) have been underwhelming. Therefore, we sought to understand the relationship between mutation and neoantigen landscape of MM patients and responsiveness to therapies. Somatic mutation burden, neoantigen load, and response to therapy were determined using interim data from the MMRF CoMMpass study (NCT01454297) on 664 MM patients...
September 22, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/29016572/financial-conflicts-of-interest-among-editorialists-in-high-impact-journals
#10
V Kaestner, V Prasad
No abstract text is available yet for this article.
September 15, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/29016571/prevalence-and-timing-of-tp53-mutations-in-del-17p-myeloma-and-effect-on-survival
#11
M Chin, J I Sive, C Allen, C Roddie, S J Chavda, D Smith, P Blombery, K Jones, G L Ryland, R Popat, A Rismani, S D'Sa, N Rabin, R E Gale, K L Yong
No abstract text is available yet for this article.
September 15, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/29016570/blinatumomab-induced-lineage-switch-of-b-all-with-t-4-11-q21-q23-kmt2a-aff1-into-an-aggressive-aml-pre-and-post-switch-phenotypic-cytogenetic-and-molecular-analysis
#12
C L Haddox, A A Mangaonkar, D Chen, M Shi, R He, J L Oliveira, M R Litzow, A Al-Kali, W J Hogan, M A Elliott
No abstract text is available yet for this article.
September 15, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/29016569/efficacy-of-pegaspargase-etoposide-methotrexate-and-dexamethasone-in-newly-diagnosed-advanced-stage-extra-nodal-natural-killer-t-cell-lymphoma-with-the-analysis-of-the-prognosis-of-whole-blood-ebv-dna
#13
J-H Liang, L Wang, R Peter Gale, W Wu, Y Xia, L Fan, J-Y Li, W Xu
No abstract text is available yet for this article.
September 15, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/29016568/the-availability-of-jobs-in-the-biopharmaceutical-industry-is-45-fold-greater-for-hematology-oncology-than-medical-specialties
#14
V Kaestner, V Prasad
No abstract text is available yet for this article.
September 15, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28885613/microrna-155-regulates-casein-kinase-1-gamma-2-a-potential-pathogenetic-role-in-chronic-lymphocytic-leukemia
#15
T Zhang, J K Davidson-Moncada, P Mukherjee, R R Furman, E Bhavsar, Z Chen, P Hakimpour, N Papavasiliou, W Tam
No abstract text is available yet for this article.
September 8, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28885612/understanding-cd30-biology-and-therapeutic-targeting-a-historical-perspective-providing-insight-into-future-directions
#16
REVIEW
C A van der Weyden, S A Pileri, A L Feldman, J Whisstock, H M Prince
CD30 is a member of the tumor necrosis factor receptor superfamily. It is characteristically expressed in certain hematopoietic malignancies, including anaplastic large cell lymphoma and Hodgkin lymphoma, among others. The variable expression of CD30 on both normal and malignant lymphoid cells has focused research efforts on understanding the pathogenesis of CD30 upregulation, its contribution to lymphomagenesis through anti-apoptotic mechanisms, and its effect on cell survival. Given the restriction of CD30 to certain tumor types, the logical extension of this has been to attempt to exploit it as a therapeutic target...
September 8, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28885611/secondary-acute-lymphoblastic-leukemia-is-a-distinct-clinical-entity-with-prognostic-significance
#17
A S Rosenberg, A Brunson, J K Paulus, J Tuscano, T Wun, T H M Keegan, B A Jonas
The effect of prior malignancy on the risk of developing, and prognosis of, acute lymphoblastic leukemia (ALL) is unknown. This observational study utilized the California Cancer Registry to estimate the risk of developing ALL after a prior malignancy using standardized incidence ratios (SIRs, 95% confidence intervals). ALL occurring after a malignancy with an SIR>1 (increased-risk (IR) malignancies) was considered secondary ALL (s-ALL). Adjusted hazard ratios (aHRs, 95% confidence intervals) compared the effect of s-ALL with de novo ALL on overall survival...
September 8, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28885610/in-silico-and-preclinical-drug-screening-identifies-dasatinib-as-a-targeted-therapy-for-t-all
#18
S Laukkanen, T Grönroos, P Pölönen, H Kuusanmäki, J Mehtonen, J Cloos, G Ossenkoppele, B Gjertsen, B Øystein, C Heckman, M Heinäniemi, M Kontro, O Lohi
No abstract text is available yet for this article.
September 8, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28862700/differences-in-genomic-patterns-and-clinical-outcomes-between-african-american-and-white-patients-with-myelodysplastic-syndromes
#19
A Nazha, K Al-Issa, B Przychodzen, N Abuhadra, C Hirsch, J P Maciejewski, M A Sekeres
No abstract text is available yet for this article.
September 1, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28862699/cxorf48-is-a-potential-therapeutic-target-for-achieving-treatment-free-remission-in-cml-patients
#20
M Matsushita, K Ozawa, T Suzuki, M Nakamura, N Nakano, S Kanchi, D Ichikawa, E Matsuki, M Sakurai, D Karigane, H Kasahara, N Tsukamoto, T Shimizu, T Mori, H Nakajima, S Okamoto, Y Kawakami, Y Hattori
Although the introduction of tyrosine kinase inhibitors (TKIs) has improved overall survival of patients with chronic myeloid leukemia (CML), about half of the patients eventually relapse after cessation of TKIs. In contrast, the remainder of the patients maintain molecular remission without TKIs, indicating that the patients' immune system could control proliferation of TKI-resistant leukemic stem cells (LSCs). However, the precise mechanism of immunity against CML-LSCs is not fully understood. We have identified a novel immune target, CXorf48, expressed in LSCs of CML patients...
September 1, 2017: Blood Cancer Journal
journal
journal
43747
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"